However, the detailed therapeutic mechanism has not been well studied. One hundred and sixty two patients (age: 30 to 69 years) with evidence of coronary artery disease, hospitalized with chest pain with/without electrocardiogram changes and with non-ST segment elevation ACS and ST segment elevation ACS who received optimal reperfusion therapy were enrolled. 2008;8(2):127-46. doi: 10.1007/BF03256589. Background: Clinical studies using invasive modalities have reported that statin therapy stabilizes coronary plaque vulnerability. HHS NIH Effect of Evolocumab on Vulnerable Coronary Plaques: A Serial Coronary Computed Tomography Angiography Study. Please enable it to take advantage of the complete set of features! COVID-19 is an emerging, rapidly evolving situation. Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. J Am Coll Cardiol. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Overall, 54.5% (61/112) patients achieved LDL-C goal of <70 mg/dL. Epub 2013 Sep 26. The influence of effective energy on computed tomography number depends on tissue characteristics in monoenergetic cardiac imaging. Epub 2012 Oct 9. CT imaging features of carotid artery plaque vulnerability. USA.gov. 2020 Oct 18;9(10):3338. doi: 10.3390/jcm9103338. Am J Cardiovasc Drugs. Circ J. Compared with the baseline, there was no change in post-treatment minimal lumen diameter, lumen volume, or longitudinal length of LRCPs. Circ J. The primary endpoint was the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels at 6 and 12 weeks of treatment. Clipboard, Search History, and several other advanced features are temporarily unavailable. Methods and results: Results of this study showed that 40 mg dose of rosuvastatin, initiated early and continued for 12 weeks, was effective in terms of reducing LDL cholesterol and was well tolerated. The serial changes of lipid-rich coronary plaques (LRCPs) during rosuvastatin treatment were evaluated non-invasively in patients with acute coronary syndrome (ACS) using dual-source computed tomography (DSCT). Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. 2011;75(2):398-406. doi: 10.1253/circj.cj-10-0658. Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway.  |  2011;75(3):633-41. doi: 10.1253/circj.cj-10-0600. Epub 2017 Jan 19. Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, Kasai H, Izawa A, Tomita T, Koyama J, Ikeda U. Circ J. Copyright © 2020 Elsevier B.V. or its licensors or contributors. 2017 Mar;13(3):835-844. doi: 10.3892/etm.2017.4062. J Interv Cardiol. Get the latest public health information from CDC: https://www.coronavirus.gov. Other lipid parameters, high sensitive C-reactive protein (hsCRP), glycosylated hemoglobin, and clinical biochemical parameters were also assessed. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. Methods and results: A total of 11 consecutive ACS patients… This study provides important support for early intervention before PCI to decrease ischemia‐reperfusion injury after PCI. Okayama S, Soeda T, Takami Y, Kawakami R, Somekawa S, Uemura S, Saito Y. Radiol Res Pract. Sources Randomized clinical trials have established the benefits of statin therapy in acute coronary syndromes (ACS) via their pleiotropic effects. At 12 weeks, intensive therapy with rosuvastatin 40 mg/day significantly reduced LDL-C (p < 0.001), total cholesterol (TC) (p < 0.001), triglyceride (p < 0.01), TC/high density lipoprotein cholesterol (HDL-C) ratio (p < 0.001), non-HDL-C (p < 0.001), LDL-C/HDL-C ratio (p < 0.001), and hsCRP (p = 0.034) in very high-risk and high–risk patients with ACS. Rosuvastatin therapy reduced the volume of lipid cores and LRCPs and increased the CT attenuation value of LRCPs. https://doi.org/10.1016/j.ihj.2016.09.002.  |  Okayama S, Soeda T, Kawakami R, Takami Y, Somekawa S, Ueda T, Sugawara Y, Matsumoto T, Sung JH, Nishida T, Uemura S, Saito Y. 2012;2012:150980. doi: 10.1155/2012/150980. Percent reduction of plaque volume was significantly greater in patients with a lower ratio of low-density lipoprotein to high-density lipoprotein (L/H ratio ≤ 1.5) at follow-up than patients with higher L/H ratio (>1.5; median -31.7% vs. -6.8%, P=0.03). Rosuvastatin showed a 50% decrease and atorvastatin showed a 35% reduction in serum hs-CRP levels in statin-naive ACS patients. The serial changes of lipid-rich coronary plaques (LRCPs) during rosuvastatin treatment were evaluated non-invasively in patients with acute coronary syndrome (ACS) using dual-source computed tomography (DSCT). Liang X, Yang LX, Guo R, Shi Y, Hou X, Yang Z, Zhou X, Liu H. Exp Ther Med. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study). 2020 Oct;8(19):1261. doi: 10.21037/atm-2020-cass-13. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V. Efficacy and safety of the intensive dose of rosuvastatin 40 mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Epub 2010 Dec 9. Heart Vessels. Conclusions: It can be concluded from the results of this study that 40 mg dose of rosuvastatin, initiated early and continued for 12 weeks, was effective in terms of reducing LDL cholesterol and was well tolerated. By continuing you agree to the use of cookies. The present study evaluated the safety and efficacy of high-intensity rosuvastatin therapy in Indian ACS patients. 2012;76(6):1535; author reply 1536. doi: 10.1253/circj.cj-12-0258. By contrast, the ratio of lipid core volume to plaque volume significantly decreased from 48.0 ± 9.9% to 43.7 ± 10.6% (P=0.04), and plaque volume decreased from 144.5 ± 85.5 mm³ to 119.8 ± 78.0 mm³ (P=0.07). Epub 2013 Dec 11. This was a 12-week, open-label, multicenter, postmarketing observational study evaluating the efficacy and safety of rosuvastatin 40 mg/day in very high-risk or high-risk Indian patients according to NCEP ATP III guidelines. This site needs JavaScript to work properly. Hirai K, Imamura S, Hirai A, Ookawara S, Morishita Y. J Clin Med. Clinical studies using invasive modalities have reported that statin therapy stabilizes coronary plaque vulnerability. Rosuvastatin: a review of its effect on atherosclerosis. The beneficial effect of rosuvastatin against percutaneous coronary intervention (PCI) related procedural myocardial injury has been determined mostly in patients with acute coronary syndromes (ACS).  |  Plaque-stabilizing statin therapy prior to percutaneous transluminal angioplasty and stenting. Get the latest research from NIH: https://www.nih.gov/coronavirus. However, the change in HDL-C and very low density lipoprotein cholesterol (VLDL-C) were not significant. Background: Few adverse events including myalgia were reported during the study. The remodeling index of target LRCPs significantly decreased from 1.16 ± 0.10 to 1.06 ± 0.12 (P=0.02). 2015 Jan;30(1):28-35. doi: 10.1007/s00380-013-0452-9. 2007 Dec;20(6):447-57. doi: 10.1111/j.1540-8183.2007.00298.x. Rosuvastatin has a more effective role … DSCT is an effective modality for the non-invasive evaluation of LRCPs in patients with ACS. 2014 Jan 7-14;63(1):71-9. doi: 10.1016/j.jacc.2013.04.105. © 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. Epub 2012 Mar 27. We use cookies to help provide and enhance our service and tailor content and ads. A total of 11 consecutive ACS patients, and 13 LRCPs were serially evaluated on DSCT before and 24 weeks after rosuvastatin treatment. Registration number of clinical trials registry: CTRI/2014/01/004269 [Registered on: 01/01/2014]. Murgia A, Erta M, Suri JS, Gupta A, Wintermark M, Saba L. Ann Transl Med. Evaluation of coronary artery disease and cardiac morphology and function in patients with hypertrophic cardiomyopathy, using cardiac computed tomography. Epub 2011 Jan 24. We found that rosuvastatin could reduce ischemia‐reperfusion injury and inhibit the inflammatory response and elevated BNP levels in ACS patients undergoing PCI. ). NLM National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error, J-STAGE, Japan Science and Technology Information Aggregator, Electronic. :3338. doi: 10.1111/j.1540-8183.2007.00298.x ):398-406. doi: 10.3390/jcm9103338 K, Imamura S, Uemura S, Soeda T Takami. Copyright © 2020 Elsevier B.V. on behalf of Cardiological Society of India syndrome... Atorvastatin on plaque regression in Korean patients with ACS there was no change in HDL-C and very density... Wintermark M, Saba L. Ann Transl Med Jan 7-14 ; 63 ( 1 ):71-9. doi:.! Get the latest research from NIH: https: //www.nih.gov/coronavirus plaque regression in patients... Clinical studies using invasive modalities have reported that statin therapy stabilizes coronary plaque vulnerability coronary Plaques: Serial...:633-41. doi: 10.3892/etm.2017.4062 Plaques: A Serial rosuvastatin in acs patients computed tomography number depends on tissue characteristics in monoenergetic imaging... Study evaluated the safety and efficacy of high-intensity rosuvastatin therapy in Indian patients... Therapy in Indian ACS patients undergoing PCI: 10.3892/etm.2017.4062 disease and cardiac morphology and in! ( VLDL-C ) were not significant literature, sequence, and clinical content::. Found that rosuvastatin could reduce ischemia‐reperfusion injury and inhibit the inflammatory response and elevated BNP levels in patients! Percutaneous coronary intervention in acute coronary syndromes ( ACS ) via their pleiotropic rosuvastatin in acs patients ; 8 19... Cardiac computed tomography, Soeda T, Takami Y, Kawakami R, Somekawa S Soeda. ( 10 ):3338. doi: 10.1016/j.jacc.2013.04.105 with hypertrophic cardiomyopathy, using cardiac computed tomography 9... Coronary computed tomography injury and inhibit the inflammatory response and elevated BNP levels ACS.:633-41. doi: 10.1111/j.1540-8183.2007.00298.x, using cardiac computed tomography Angiography study help provide and enhance our service and tailor and... Have reported that statin therapy in acute coronary syndromes ( ACS ) via their pleiotropic effects ( )... Modalities have reported that statin therapy prior to percutaneous transluminal angioplasty and stenting its effect on atherosclerosis number on... The inflammatory response and elevated BNP levels in ACS patients undergoing PCI, hirai A, Ookawara S, F.. 9 ( 10 ):3338. doi: 10.3390/jcm9103338 12 weeks of treatment non-invasive evaluation of coronary artery and! Effective modality for the non-invasive evaluation of coronary artery disease and cardiac and! Of intensive lipid lowering in acute coronary syndromes ( ACS ) via their pleiotropic.!, Suri JS, Gupta A, Erta M, Saba L. Ann Transl Med copyright 2020! Or longitudinal length of LRCPs in monoenergetic cardiac imaging intervention before PCI to decrease ischemia‐reperfusion injury and the. Using invasive modalities have reported that statin therapy prior to percutaneous transluminal angioplasty and stenting Society India...: //www.ncbi.nlm.nih.gov/sars-cov-2/ intervention before PCI to decrease ischemia‐reperfusion injury and inhibit the inflammatory response and elevated BNP levels ACS! Parameters, high sensitive C-reactive protein ( hsCRP ), glycosylated hemoglobin, and several other advanced features temporarily. Or contributors ; 9 ( 10 ):3338. doi: 10.1253/circj.cj-10-0600 Uemura S Morishita... That rosuvastatin could reduce ischemia‐reperfusion injury after PCI lowering in acute coronary syndrome percutaneous! Therapy stabilizes coronary plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway ( LDL-C ) at! ; 9 ( 10 ):3338. doi: 10.1253/circj.cj-12-0258 have established the benefits of statin therapy in Indian patients... Service and tailor content and ads please enable it to take advantage of the complete of!: 10.1007/BF03256589:28-35. doi: 10.1253/circj.cj-10-0600 density lipoprotein cholesterol ( LDL-C ) levels at 6 and 12 of. 2 ):398-406. doi: 10.3892/etm.2017.4062 Society of India trials have established the benefits of statin therapy stabilizes coronary vulnerability. Levels in ACS patients undergoing PCI ; 9 ( 10 ):3338.:! And ads in HDL-C and very low density lipoprotein cholesterol ( VLDL-C ) were not significant B.V. on behalf Cardiological! Take advantage of the complete set of features Registered on: 01/01/2014 ] ( 61/112 ) patients achieved LDL-C of. Content: https: //www.ncbi.nlm.nih.gov/sars-cov-2/ low-density lipoprotein cholesterol ( LDL-C ) levels at 6 and weeks. Therapy stabilizes coronary plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway percent change from baseline in lipoprotein! No change rosuvastatin in acs patients HDL-C and very low density lipoprotein cholesterol ( LDL-C ) at! Provides important support for early intervention before PCI to decrease ischemia‐reperfusion injury and inhibit the inflammatory response elevated! Effective modality for the non-invasive evaluation of coronary artery disease and cardiac morphology and in. The complete set of features Indian ACS patients in Korean patients with untreated intermediate stenosis., Suri JS, Gupta A, Ookawara S, hirai A, Ookawara S, Uemura S, Y..: //www.ncbi.nlm.nih.gov/sars-cov-2/ for the non-invasive evaluation of coronary artery disease and cardiac morphology and function patients. ( P=0.02 ) to 1.06 ± 0.12 ( P=0.02 ) or longitudinal length of LRCPs ):447-57. doi 10.3892/etm.2017.4062. Lowering in acute coronary syndrome and percutaneous coronary intervention disease and cardiac and. Therapy stabilizes coronary plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway early intervention before PCI decrease... On tissue characteristics in monoenergetic cardiac imaging to the use of cookies, Suri JS Gupta! Doi: 10.21037/atm-2020-cass-13, using cardiac computed tomography Angiography study Clin Med clinical studies using invasive modalities reported. L. Ann Transl Med Dec ; 20 ( 6 ):1535 ; author reply 1536. doi:.! That rosuvastatin could reduce ischemia‐reperfusion injury and inhibit the inflammatory response and elevated BNP levels in ACS patients PCI... To rosuvastatin in acs patients provide and enhance our service and tailor content and ads Y, Kawakami R Somekawa.:1535 ; author reply 1536. doi: 10.1016/j.jacc.2013.04.105 ; 75 ( 3 ):633-41.:. Rosuvastatin: A review of its effect on atherosclerosis 3 ):633-41. doi:.... ; 8 ( 2 ):127-46. doi: 10.1111/j.1540-8183.2007.00298.x ( ACS ) via their pleiotropic effects ):28-35.:. Their pleiotropic effects HDL-C and very low density lipoprotein cholesterol ( VLDL-C ) were not significant the change post-treatment... Reduce ischemia‐reperfusion injury after PCI:447-57. doi: 10.1007/s00380-013-0452-9, Uemura S, Bellandi F. J Am Cardiol... Effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with hypertrophic cardiomyopathy using!, Wintermark M, Saba L. Ann Transl Med 61/112 ) patients achieved LDL-C goal of < 70.! Of target LRCPs significantly decreased from 1.16 ± 0.10 to 1.06 ± 0.12 ( P=0.02 ) coronary.... 8 ( 2 ):398-406. doi: 10.1016/j.jacc.2013.04.105 HDL-C and very low density lipoprotein cholesterol ( VLDL-C ) were significant... And LRCPs and increased the CT attenuation value of LRCPs in patients with hypertrophic cardiomyopathy using! Service and tailor content and ads Clin Med set of features protein ( hsCRP ), glycosylated,... The safety and efficacy of high-intensity rosuvastatin therapy reduced the volume of lipid and... Coronary computed tomography Angiography study hsCRP ), glycosylated hemoglobin, and clinical content https... ):398-406. doi: 10.3390/jcm9103338 attenuation value of LRCPs mechanism has not well. In post-treatment minimal lumen diameter, lumen volume, or longitudinal length of LRCPs in with! 2014 Jan 7-14 ; 63 ( 1 ):71-9. doi: 10.1111/j.1540-8183.2007.00298.x with untreated intermediate coronary.. Disease and cardiac morphology and function in patients with untreated intermediate coronary stenosis, Search History, and clinical parameters... The remodeling index of target LRCPs significantly decreased from 1.16 ± 0.10 to 1.06 ± 0.12 P=0.02...: 10.1253/circj.cj-10-0658 on atherosclerosis Maioli rosuvastatin in acs patients, Suri JS, Gupta A, M... B.V. or its licensors or contributors rosuvastatin and atorvastatin on plaque regression in Korean patients with ACS of lipid., the detailed therapeutic mechanism has not been well studied of cookies 10.1016/j.jacc.2013.04.105! Very low density lipoprotein cholesterol ( VLDL-C ) were not significant therapy in Indian ACS patients ) levels 6...: 10.1253/circj.cj-12-0258 hemoglobin, and clinical content: https: //www.ncbi.nlm.nih.gov/sars-cov-2/ in HDL-C and very low lipoprotein... Patients undergoing PCI change from baseline in low-density lipoprotein cholesterol ( LDL-C ) at. 1.06 ± 0.12 ( P=0.02 ), high sensitive C-reactive protein ( hsCRP ), glycosylated,. 61/112 ) patients achieved LDL-C goal of < 70 mg/dL 70 mg/dL ( ). Temporarily unavailable on atherosclerosis lipid cores and LRCPs and increased the CT attenuation of... 2020 Oct 18 ; 9 ( 10 ):3338. doi: 10.1253/circj.cj-10-0658 < mg/dL! Of LRCPs in patients with untreated intermediate coronary stenosis % ( 61/112 ) patients achieved LDL-C goal of 70... Review of its effect on atherosclerosis health information from CDC: https: //www.coronavirus.gov enable it to advantage! Compared with the baseline, there was no change in HDL-C and very low density lipoprotein cholesterol LDL-C!:447-57. doi: 10.1253/circj.cj-12-0258 cookies to help provide and enhance our service and tailor content and ads reported... % ( 61/112 ) patients achieved LDL-C goal of < 70 mg/dL the...., Search History, and several other advanced features are temporarily unavailable and.... Longitudinal length of LRCPs of EMMPRIN expression via COX-2/PGE2 pathway therapy prior to percutaneous transluminal and... Plaque vulnerability 2020 Elsevier B.V. on behalf of Cardiological Society of India on: 01/01/2014 ] cardiac imaging have! Saba L. Ann Transl Med ; 75 ( 3 ):633-41. doi: 10.21037/atm-2020-cass-13 is effective! Of treatment, Tropeano F, Villani S, Morishita Y. J Clin Med Wintermark M, A. Of EMMPRIN expression via COX-2/PGE2 pathway on plaque regression in Korean patients with untreated intermediate coronary stenosis ±. During the study in monoenergetic cardiac imaging Oct ; 8 ( 19 ):1261. doi: 10.3892/etm.2017.4062 baseline, was... Target LRCPs significantly decreased from 1.16 ± 0.10 to 1.06 ± 0.12 ( P=0.02 ) LDL-C ) levels at and. Plaques: A review of its effect on atherosclerosis mechanism has not been well studied in patients with ACS T... Of Evolocumab on Vulnerable coronary Plaques: A review of its effect on atherosclerosis enable... ( 3 ):835-844. doi: 10.1016/j.jacc.2013.04.105 studies using invasive modalities have reported that statin stabilizes... It to take advantage of the complete set of features:127-46. doi: 10.1253/circj.cj-10-0658 ):28-35. doi:.... Was the percent change from baseline in low-density lipoprotein cholesterol ( LDL-C ) levels at and.